Menu

Jim Bridenstine Confirmed to Lead NASA

The US Senate narrowly approved the politician, who does not have a science background.

Apr 19, 2018
Kerry Grens

WIKIMEDIA, UNITED STATES CONGRESSAlong party lines, the US Senate has confirmed Congressman Jim Bridenstine (R-OK) as the new head of NASA today (April 19). The approval comes after a drawn-out nomination period during which senators questioned his qualifications—Bridenstine was a pilot and politician, but never a scientist.

“The NASA administrator should be a consummate space professional, that’s what this senator wants,” Senator Bill Nelson (D-FL), who opposed the nominee, said yesterday, according to Politico. “That space professional ought to be technically and scientifically competent, and a skilled executive.”

Bridenstine was a Navy pilot, who has represented Oklahoma’s first congressional district since 2013. Science reports that as NASA Administrator, Bridenstine has his work cut out for him, including dealing with a delayed telescope launch and another planned telescope the White House wants to abandon. The New York Times notes that under President Donald Trump’s administration, NASA has set its focus on returning humans to the moon.

Trump nominated Bridenstine in September 2017, following the departure of Charles Bolden upon the President’s inauguration. Robert Lightfoot, a longtime NASA official, had been acting director. According to The Times, Bridenstine is the first elected official to run the agency.

“I was not enthused about the nomination. Nothing personal about Mr. Bridenstine. NASA is an organization that needs to be led by a space professional,” Senator Marco Rubio (R-FL), who voted in favor of confirmation, said Thursday, according to The Washington Post. But “my view of it is, and it has been the tradition of the Senate for the entire distance of the republic, that we give great deference to the president on choosing qualifications.” 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.